by Peter Ciszewski | Apr 21, 2018
Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals provides a compnay overview focusing on Lenabasum, a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in...
by Peter Ciszewski | Apr 19, 2018
Jeff Marrazzo, Co-Founder and CEO of Spark Therapeutics, discusses working with advocacy groups and the importance of recognizing patients in all the work they...
by Peter Ciszewski | Apr 18, 2018
The Food and Drug Administration (FDA) approved Crysvita (burosumab-twza) as the first treatment for patients with x-linked hypophosphatemia (XLH). Ultragenyx Pharmaceutical and Kyowa Hakko Kirin developed Crysvita, which is an antibody that blocks fibroblast growth...
by Peter Ciszewski | Apr 18, 2018
Rob Neville of Savara Pharmaceuticals discusses his company’s cystic fibrosis program. Savara initiated its pivotal Phase 3 AVAIL Study of AeroVanc for the treatment of MRSA in Cystic Fibrosis patients in Q3 2017. There are about 30,000 people living with...
by Peter Ciszewski | Apr 18, 2018
Researchers at the National Institutes of Health (NIH) worked with 15 patients from around the world to solve the genetic basis of a rare bone disorder’s origins. The rare disorder, known as melorheostosis (or “dripping candle wax” bone disease) causes excess...
